Volumetric and MGMT Parameters in Glioblastoma Patients: Survival Analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Jan 5

PMID 22214427

Citations 43

Authors

Georgios Iliadis

Vassiliki Kotoula

Athanasios Chatzisotiriou

Despina Televantou

Anastasia G Eleftheraki

Sofia Lambaki

Despina Misailidou

Panagiotis Selviaridis

George Fountzilas

Affiliations

Soon will be listed here.

Abstract

Background: In this study several tumor-related volumes were assessed by means of a computer-based application and a survival analysis was conducted to evaluate the prognostic significance of pre- and postoperative volumetric data in patients harboring glioblastomas. In addition, MGMT (O6-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development.

Methods: We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy with concomitant adjuvant temozolomide. For the purpose of volumetry T1 and T2-weighted magnetic resonance (MR) sequences were used, acquired both pre- and postoperatively (pre-radiochemotherapy). The volumes measured on preoperative MR images were necrosis, enhancing tumor and edema (including the tumor) and on postoperative ones, net-enhancing tumor. Age, sex, performance status (PS) and type of operation were also included in the multivariate analysis. MGMT was assessed for promoter methylation with Multiplex Ligation-dependent Probe Amplification (MLPA), for RNA expression with real time PCR, and for protein expression with immunohistochemistry in a total of 44 cases with available histologic material.

Results: In the multivariate analysis a negative impact was shown for pre-radiochemotherapy net-enhancing tumor on the overall survival (OS) (p = 0.023) and for preoperative necrosis on progression-free survival (PFS) (p = 0.030). Furthermore, the multivariate analysis confirmed the importance of PS in PFS and OS of patients. MGMT promoter methylation was observed in 13/23 (43.5%) evaluable tumors; complete methylation was observed in 3/13 methylated tumors only. High rate of MGMT protein positivity (> 20% positive neoplastic nuclei) was inversely associated with pre-operative tumor necrosis (p = 0.021).

Conclusions: Our findings implicate that volumetric parameters may have a significant role in the prognosis of GBM patients. Furthermore, volumetry could help not only to improve the prediction of outcome but also the outcome itself by identifying patients at high risk of treatment failure and, thus, seek alternative treatment for these patients. In this small series, MGMT protein was associated with less aggressive tumor characteristics.

Citing Articles

Shape matters: unsupervised exploration of IDH-wildtype glioma imaging survival predictors.

Foltyn-Dumitru M, Mahmutoglu M, Brugnara G, Kessler T, Sahm F, Wick W Eur Radiol. 2024; 35(3):1351-1360.

PMID: 39251442 PMC: 11835892. DOI: 10.1007/s00330-024-11042-6.

Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis.

Li L, Xiao F, Wang S, Kuang S, Li Z, Zhong Y Sci Rep. 2024; 14(1):16031.

PMID: 38992201 PMC: 11239670. DOI: 10.1038/s41598-024-66653-2.

Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis.

Valenzuela-Fuenzalida J, Moyano-Valarezo L, Silva-Bravo V, Milos-Brandenberg D, Orellana-Donoso M, Nova-Baeza P J Clin Med. 2024; 13(12).

PMID: 38929990 PMC: 11204640. DOI: 10.3390/jcm13123460.

Tumour Size and Overall Survival in a Cohort of Patients with Unifocal Glioblastoma: A Uni- and Multivariable Prognostic Modelling and Resampling Study.

Fatania K, Frood R, Mistry H, Short S, OConnor J, Scarsbrook A Cancers (Basel). 2024; 16(7).

PMID: 38610979 PMC: 11011077. DOI: 10.3390/cancers16071301.

Association of MRI Volume Parameters in Predicting Patient Outcome at Time of Initial Diagnosis of Glioblastoma.

Lau K, Ruisi I, Back M Brain Sci. 2023; 13(11).

PMID: 38002539 PMC: 10670247. DOI: 10.3390/brainsci13111579.

References

Laws E, Parney I, Huang W, Anderson F, Morris A, Asher A . Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003; 99(3):467-73. DOI: 10.3171/jns.2003.99.3.0467. View

Crawford F, Khayal I, McGue C, Saraswathy S, Pirzkall A, Cha S . Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol. 2008; 91(3):337-51. PMC: 3022444. DOI: 10.1007/s11060-008-9719-x. View

Jeuken J, Cornelissen S, Vriezen M, Dekkers M, Errami A, Sijben A . MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007; 87(10):1055-65. DOI: 10.1038/labinvest.3700664. View

Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S . Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2009; 11(6):842-52. PMC: 2802404. DOI: 10.1215/15228517-2009-005. View

Tralins K, Douglas J, Stelzer K, Mankoff D, Silbergeld D, Rostomily R . Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002; 43(12):1667-73. View

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

Plataniotis G, Theofanopoulou M, Kalogera-Fountzila A, Haritanti A, Ciuleanou E, Ghilezan N . Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys. 2004; 59(4):1018-26. DOI: 10.1016/j.ijrobp.2004.01.021. View

Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M . Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009; 15(21):6683-93. DOI: 10.1158/1078-0432.CCR-08-2801. View

Thiele F, Ehmer J, Piroth M, Eble M, Coenen H, Kaiser H . The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol. 2009; 54(18):5525-39. DOI: 10.1088/0031-9155/54/18/012. View

10.

Andreopoulou E, Andreopoulos D, Adamidis K, Fountzilas G, Dimopoulos M, Aravantinos G . Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res. 2002; 22(3):1903-8. View

11.

Shweiki D, Itin A, Soffer D, Keshet E . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359(6398):843-5. DOI: 10.1038/359843a0. View

12.

Souhami L, Seiferheld W, Brachman D, Podgorsak E, Werner-Wasik M, Lustig R . Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004; 60(3):853-60. DOI: 10.1016/j.ijrobp.2004.04.011. View

13.

Grabenbauer G, Gerber K, Ganslandt O, Richter A, Klautke G, Birkmann J . Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009; 75(1):164-9. DOI: 10.1016/j.ijrobp.2009.04.015. View

14.

Raza S, Lang F, Aggarwal B, Fuller G, Wildrick D, Sawaya R . Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery. 2002; 51(1):2-12; discussion 12-3. DOI: 10.1097/00006123-200207000-00002. View

15.

Gorlia T, van den Bent M, Hegi M, Mirimanoff R, Weller M, Cairncross J . Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2007; 9(1):29-38. DOI: 10.1016/S1470-2045(07)70384-4. View

16.

Brell M, Tortosa A, Verger E, Gil J, Vinolas N, Villa S . Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005; 11(14):5167-74. DOI: 10.1158/1078-0432.CCR-05-0230. View

17.

Cao Y, Nagesh V, Hamstra D, Tsien C, Ross B, Chenevert T . The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006; 66(17):8912-7. DOI: 10.1158/0008-5472.CAN-05-4328. View

18.

Burger P, Heinz E, Shibata T, Kleihues P . Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg. 1988; 68(5):698-704. DOI: 10.3171/jns.1988.68.5.0698. View

19.

Oh J, Henry R, Pirzkall A, Lu Y, Li X, Catalaa I . Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. 2004; 19(5):546-54. DOI: 10.1002/jmri.20039. View

20.

Keles G, Anderson B, Berger M . The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999; 52(4):371-9. DOI: 10.1016/s0090-3019(99)00103-2. View